IMB Dx, Inc. (KOSDAQ:461030)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,080.00
-90.00 (-1.10%)
Aug 28, 2025, 3:30 PM KST
-1.10%
Market Cap113.26B
Revenue (ttm)3.83B
Net Income (ttm)-7.97B
Shares Out14.02M
EPS (ttm)-569.15
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,782
Average Volume48,229
Open8,100.00
Previous Close8,170.00
Day's Range8,000.00 - 8,120.00
52-Week Range7,180.00 - 23,500.00
Betan/a
RSI51.85
Earnings Daten/a

About IMB Dx

IMB Dx, Inc. provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals; and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test. The company also provides CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer ea... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 461030
Full Company Profile

Financial Performance

In 2024, IMB Dx's revenue was 3.41 billion, a decrease of -15.40% compared to the previous year's 4.03 billion. Losses were -9.58 billion, -8.06% less than in 2023.

Financial Statements

News

There is no news available yet.